The expression of VEGF and the relapse-free survival rate of breast cancer patients are inversely related. While VEGF induces the proliferation and migration of vascular endothelial cells, its function in breast cancer cells is not well studied. We reported previously that ®bronectin increased VEGF-dependent migration in breast cancer cells. Since VEGF has an extracellular matrix (ECM)-binding domain and possesses binding anity for heparin, we sought to determine the eects of VEGF in breast cancer cells and the role of heparin and/ or ®bronectin in VEGF-induced signaling. Cells grown on plastic were compared to those grown on ®bronectin or to those grown on plastic in the presence of heparin, and analysed for intracellular signaling, proliferation and migration in response to VEGF 165 . Both heparin and ®bronectin enhanced the binding of VEGF to T47D cells. After treatment with VEGF, [ 3 H]thymidine incorporation, c-fos induction, and the number of migrating cells were signi®cantly higher (*twofold) in cells grown on ®bronectin or in cells grown on plastic in the presence of heparin when compared to those grown on plastic only. Likewise, tyrosine phosphorylation of VEGF receptors, MAPK activity and PI3-kinase activity were all severalfold higher in cells seeded on ®bronectin or in the presence of heparin as compared to cells exposed to VEGF alone. VEGF-dependent c-fos induction was found to be regulated through a MAPK-dependent, butIntroduction Vascular endothelial growth factor (VEGF) is angiogenic in vitro (Pepper et al., 1992) and in vivo (Plouet et al., 1989) by inducing the proliferation (Yu and Sato, 1999) and migration (Radisavljevic et al., 2000) of vascular endothelial cells. VEGF is produced in numerous cell types such as tumor cells, smooth muscle cells, mesangial cells, macrophages, and osteoblasts (Klagsbrun and D'Amore, 1996) . It is a homodimer ) that occurs in ®ve isoforms, speci®cally: VEGF 121 , VEGF 145 , VEGF 165 , VEGF 189 and VEGF 206 , as a result of alternative splicing from a single gene (Houck et al., 1991) . Of these, VEGF 121 and VEGF 165 are the most abundant and potent isoforms (Bacic et al., 1995) . While VEGF 121 lacks an ECM-binding domain and is secreted only in medium, VEGF 165 is found to be both cell-associated and secreted in medium (Park et al., 1993) .
Flt-1, Flk-1/KDR and Flt-4 belong to the family of VEGF receptors (Shibuya et al., 1999) . All three receptors have an extracellular domain containing seven immunoglobulin-like loops and an intracellular domain characterized by split tyrosine kinase motifs (Shibuya et al., 1999) . Upon activation, the phosphorylated tyrosines act as docking sites for adaptor-signaling molecules and non-receptor kinases (Dougher-Vermazen et al., 1994) , thereby generating signaling cascades such as MAPK (Malarkey et al., 1995) and PI3K/Akt (Guo et al., 1995) .
VEGF and the ®broblast growth factor (FGF) group of growth factors are characterized by their binding anity for heparin (Folkman and Klagsbrun, 1987; Tischer et al., 1989) . Such binding anity was shown to have a biological eect, enabling a productive interaction between the growth factor and its cellsurface receptors (Taga et al., 1989; Yayon et al., 1991) . Heparinase treatment of endothelial cells inhibited endothelial cell proliferation and in vivo neovascularization (Sasisekharan et al., 1994) , emphasizing the role of heparin-like molecules in angiogenesis. In some cell types, the presence of heparin-like molecules is essential for the binding of b-FGF to its receptors (Rapraeger et al., 1991; Yayon et al., 1991) , thereby protecting b-FGF from heat and acidic inactivation (Gospodarowicz and Cheng, 1986) . The interaction of VEGF with heparin is more modest as compared to that of b-FGF (Taga et al., 1989; Yayon et al., 1991) , and is comparable to the modest anity shown by PDGF, a member of the same group of growth factors (Hicks et al., 1989) . Although having a relatively weak interaction with VEGF, heparin and heparan sulfate proteoglycans (HSPGs) are able to enhance the interaction of VEGF with its receptors (Gengrinovitch et al., 1999) . The binding of VEGF to its cell-surface receptors was restored by the addition of heparin after the concentration of heparin-like molecules on the cell surface was reduced by heparinase treatment (Gengrinovitch et al., 1999; Gitay-Goren et al., 1992) . However, the binding of VEGF 121 , a truncated variant that lacks a heparinbinding domain, could not be restored by the addition of heparin-like molecules .
Breast cancer cells express both VEGF (Blancher et al., 2000; Price et al., 2001 ) and VEGF receptors (Price et al., 2001; Soker et al., 1996) . Heparin/ HSPGs were shown to enhance and stabilize the binding of VEGF to its receptors in endothelial and breast cancer cells (Gitay-Goren et al., 1992; Soker et al., 1996) . However, none of the previous studies have shown whether the enhanced binding of VEGF to its receptors is associated with functional responses in breast cancer cells. Only cells passaged on a membrane coat containing ®bronectin responded to VEGF by increased migration (Price et al., 2001) . Fibronectin (Ruoslahti, 1991) and heparin (Halper, 1990) bind to the cell surface through receptors and high anity sites, respectively. VEGF (Cardin and Weintraub, 1989) , VEGF-receptors (Dougher et al., 1997) , and ®bronectin (Ruoslahti et al., 1981) possess a highly basic region that confers strong anity for heparin. Furthermore, heparin and HSPGs enhance the binding of VEGF to its receptors (Gitay-Goren et al., 1992) and are necessary for the biological actions of b-FGF (Rapraeger et al., 1991; Yayon et al., 1991) . Therefore, we hypothesize that T47D cell responsiveness to VEGF might require the involvement of extracellular matrix components. This study was undertaken to examine the eects of ECM components, ®bronectin and heparin, on the biological responsiveness of T47D breast cancer cells to VEGF 165 .
Results

Effect of fibronectin and heparin on T47D cell migration
We reported recently the increased migration of breast cancer cells upon their stimulation with VEGF 165 , in the presence of ®bronectin (Price et al., 2001) . This observation was further con®rmed in the present study, where VEGF increased T47D cell migration from 35+14 cells on Matrigel to 88+2 cells in the presence of ®bronectin (Figure 1a ). Because VEGF 165 is characterized by an extracellular matrix-binding domain and by its binding anity for heparin, we wanted to extend this study and test whether this polyanion would also aect the VEGF 165 -induced migration of breast cancer cells.
Migration of T47D cells was tested in 24-well plates containing transwell membranes coated with matrigel or matrigel+®bronectin. Approximately 30 to 40 cells migrated onto transwell membranes in the control wells or in wells treated with heparin alone (Figure 1a,b) . When cells were treated with heregulin, a known stimulator of breast cancer cell migration, 104+11 cells migrated onto the transwell membrane. Upon stimulation with VEGF, cells seeded on matrigel alone (Figure 1a ). The migration rate of VEGFstimulated cells was signi®cantly increased to 78+4 by the addition of heparin in the moment of cell passage ( Figure 1a ). Addition of ®bronectin to the matrigel coat further increased the number of migrating cells after treatment with heregulin, VEGF or VEGF plus heparin to 122+8, 88+2 and 101+10, respectively ( Figure 1a ). As we showed previously, the addition of ®bronectin did not aect the migration of nontreated cells or cells treated with heparin alone. The number of migrating cells was not increased either upon treatment with VEGF 121 alone or VEGF 121 in the presence of heparin (1 mg/ml) on both protein coatings (Figure 1a ), suggesting the requirement for an ECM-binding domain of this growth factor. To elucidate the mechanism and signaling pathway that regulates this migration in T47D cells, cells were pretreated with genistein, PD98059, U0126, or LY294002 prior to detachment, or with blocking anti-b 1 or blocking antia 6 integrin antibodies prior to treatment with VEGF in the presence of heparin (Figure 1b ). In the presence of heparin and VEGF, 178+18 cells migrated to the membrane. This migration was decreased by approximately 50% after pretreatment with PD98059, U0126, or with blocking anti-b 1 integrin antibody, while blocking anti-a 6 integrin did not have a signi®cant eect (Figure 1b) , indicating a partial involvement of b 1 integrin in this process. When cells were pretreated with genistein or LY294002, the VEGF-induced migratory response was totally abolished (being 49+11 and 67+9, respectively, Figure 1b ), suggesting its dependence on both tyrosine kinase and PI3K.
Heparin and fibronectin affect VEGF binding to T47D breast cancer cells
Heparin has been shown to enhance the binding and to stabilize the complex between VEGF and its receptors in endothelial cells and MDA-MB-231 breast cancer cells (Gitay-Goren et al., 1992; Soker et al., 1996) 
Effect of ECM on the VEGF-dependent mitogenic response in T47D cells
Since ®bronectin and/or heparin increased T47D cell migration in response to VEGF and enhanced the binding of VEGF to T47D cells, we analysed the eect of ECM components on cell proliferation. To study the eect of substratum on mitogenic response, the incorporation of [ Oncogene Effect of ECM and VEGF in breast cancer T Miralem et al become synchronized and begin to proliferate uniformly when fed with FBS or growth factors (Kodali et al., 1994) . Heregulin is a potent mitogen for breast cancer cells (Lupu et al., 1995; Normanno et al., 1994) Figure 3a) .
To address the speci®city of the ®bronectin eect on the mitogenic response, cells were seeded on several other ECM components. At peak incorporation (18 h), the eect of matrigel, collagen types I and IV and poly-L-lysine, was tested and compared to those cells grown on plastic or ®bronectin. A signi®cantly low mitogenic response was observed in cells grown on collagen type IV or poly-L-lysine, which was similar to the cells grown on plastic or to untreated (control) cells ( Figure  3b ). Cells seeded on matrigel or collagen type I had a comparable increase in VEGF-dependent [ 3 H]thymidine incorporation, which was approximately twotimes higher than in the control cells (203+9 and 206+13%, respectively). However, ®bronectin caused the most prominent increase in mitogenic response (257+10%, Figure 3b ) relative to the other matrices. Therefore, we have chosen to elucidate the role of ®bronectin in VEGF-dependent signaling in breast cancer cells, as described below.
The heparin homologue of HSPGs stabilizes the complex between VEGF and its receptors and increases their binding due to several basic residues on both the ligand (Templeton, 1992) and receptor (Dougher et al., 1997) . Thus, this polyanion was used to test whether it would aect VEGF-dependent mitogenic response in T47D cells. FBS strongly increased [ 3 H]thymidine incorporation at the peak of DNA synthesis (7669+ 920 c.p.m. for FBS vs 3349+335 c.p.m. for control which is taken as 100%, P50.01). An additional twofold increase in DNA synthesis was observed upon FBS treatment of cells that were grown on ®bronectin (461+21%, FBS on FN; vs 229+12%, FBS on plastic; P50.01, Table 1 ). In the presence of heparin, VEGF was able to increase DNA synthesis 2 ± 3 times that in the control cells (225+13%, VEGF+H vs 110+9%, VEGF alone, vs 100+10%, untreated cells), even though cells were seeded on plastic (Table 1) . A similar increase in DNA synthesis was observed in cells grown on ®bronectin after treatment with VEGF. Furthermore, heparin's presence further increased VEGFdependent [ 3 H]thymidine incorporation (298+12%, FN+VEGF+H vs 246+11%, FN+VEGF) in T47D cells seeded on ®bronectin (Table 1) , suggesting a stronger eect of heparin. Fibronectin or heparin alone or their combination did not dramatically aect DNA synthesis over the course of 18 h (100+20%, 95+11%, and 93+9%, respectively). Therefore, the apparent eects of heparin and ®bronectin on VEGFdependent cell migration in the matrigel invasion assay may be attributed to their demonstrated eects on cell proliferation.
To address the mechanism by which ®bronectin and heparin cause the increased VEGF-dependent mitogenic response, T47D cells were treated with VEGF 121 or EGF. We observed that VEGF 121 , a shorter form of the VEGF protein which lacks an ECM-binding domain, was fully active and was able to induce DNA synthesis in endothelial cells (data not shown). However, , collagen types I and IV (COL-1, COL-4) and poly-L lysine (POL-L), treated with VEGF (100 ng/ml), and processed for determination of the incorporated radioactivity at peak value (18 h, see Figure 3a ) and compared to non treated cells (control) 165 , both on ®bronectin, Table 1 ).
The increased mitogenic response could be a consequence of more cells initially attaching to ®bronec-tin. To address this possibility, nonlabeled cells or cells labeled with 3 H-thymidine were passaged onto either ®bronectin or plastic, allowed to attach for 1 h and then the number of adherent cells or radioactivity was counted. Two separate experiments showed no dierence in the attachment of T47D cells to either plastic or ®bronectin (Table 2) . Therefore, the increased [ 3 H]thymidine incorporation after treatment with VEGF (following a 48-h starvation period) is not due to initial greater adhesion, but rather to an increase of cell mitogenic response in the presence of ®bronectin.
Effect of heparin and fibronectin on VEGF-dependent c-fos induction
Induction of the protooncogene c-fos is an early indicator of cell entry into the cell cycle. c-fos mRNA levels were reported to be maximal 30 ± 60 min after the stimulation of quiescent breast cancer cells with heregulin (Sepp-Lorenzino et al., 1996) . Similar amounts of total RNA were loaded in all blots as indicated in the lower panels after probing with an 18S cDNA probe. Cells grown on plastic showed a transient increase in c-fos mRNA level in response to VEGF, although it was a much lower response as compared to cells treated with heregulin (Figure 4a,c) . In the presence of heparin, a signi®cant increase in VEGF-dependent c-fos mRNA level was observed, supporting the results showing a mitogenic response (Figure 4b) . In additional experiments, we further compared c-fos mRNA levels 30 min after stimulation with VEGF in cells plated on plastic in the presence of chondroitin sulfate or dextran sulfate or in cells plated on ®bronectin in the presence of heparin (Figure 4b ). Dextran sulfate, an unrelated polyanion, increased VEGF-induced c-fos transcription similar to heparin, while chondroitin sulfate, a glycosaminoglycan control, did not signi®cantly aect this induction. Because the c-fos mRNA level, in response to dextran sulfate alone, was almost as high as with VEGF and dextran sulfate together, it suggests that heparin possesses a VEGF- T47D cells were seeded either on plastic or on ®bronectin-coated 24-well plates and rendered quiescent. Cells were then stimulated either with VEGF 165 (100 ng/ml), VEGF 121 (100 ng/ml) or EGF (10 ng/ml), in the presence or absence of heparin (1 mg/ml), or with FBS (10%) or left untreated`0'. Some cells were treated with blocking anti-b 1 integrin or with blocking anti-a 6 integrin antibodies prior to the treatment with VEGF 165 , and some cells were treated with heparin (1 mg/ml) alone. Cells were then processed in the same way as described in Figure 3b to measure the incorporated [ (Figure 4b ) that was further increased when heparin was present in the medium. This enhancing eect of heparin is similar to that observed when the mitogenic response was tested (Table 1) .
We next examined a series of kinase inhibitors to characterize the pathway by which c-fos is induced in T47D cells in response to VEGF. Cells were pretreated with genistein, PD98059 or LY294002 before the addition of VEGF and then tested for the level of cfos mRNA (Figure 4c ). While genistein inhibited tyrosine kinases and downstream pathways including MAPK and PI3K, PD98059 inhibited only MEK/ MAPK-dependent signaling (Dudley et al., 1995) and LY294002 inhibited only the PI3K/Akt pathway (Vlahos et al., 1994) . None of the inhibitors aected a basal level of c-fos mRNA. Genistein and PD98059 abolished the VEGF-dependent increase in c-fos mRNA level while LY294002 had a modest suppressive eect (Figure 4c ), suggesting the MAPK dependence of c-fos induction in these cells.
Heparin and fibronectin affect VEGF-dependent MAPK activation
Several pathways are known to be involved in c-fos induction, with one acting through the Erk family of MAPK (Treisman, 1992) . Recently, we showed that T47D cells responded to VEGF with a modest MAPK activation which had maximal activity at 15 min (Price et al., 2001) . Thus, at 15 min, we tested the eects of heparin and ®bronectin on VEGFdependent MAPK activation. Phosphorylation as well as activation of MAPK were analysed by using phospho-speci®c antibody and an in vitro kinase assay, respectively. Quiescent cells on plastic, ®bro-nectin, a collagen type IV, or cells treated with heparin alone showed very low levels of either MAPK phosphorylation or activity ( Figure 5 ). When cells were treated with VEGF, a strong increase in the phosphorylation (Figure 5b ) and activity (Figure 5a ) of Erk occurred. However, this activity was still several times lower than that elicited by heregulin. This VEGF-induced increase was sensitive to pretreatment with the MAPK kinase (MEK1/2) inhibitor, PD98059, suggesting a MAPK-dependent process. The response to VEGF was greatly enhanced by the presence of heparin and dextran sulfate, whereas chondroitin sulfate was without eect (Figure 5a,b) . Heparin also slightly increased the level of MAPK phosphorylation in cells seeded on ®bronectin in response to VEGF, which otherwise was similar to the cells grown on plastic (Figure 5b) . Consistent with the mitogenic response, MAPK activity was also low on collagen type IV when compared to that on ®bronectin (Figure 5a ). The total amount of MAPK protein detected by Western blotting was the same in cells grown on ®bronectin or plastic as indicated (lower panels, Figure 5a,b) . Effect of fibronectin and heparin on VEGF receptor tyrosine phosphorylation VEGF activates the Ras pathway through protein tyrosine kinase receptors (Dougher-Vermazen et al., 1994; Sawano et al., 1996) , and subsequently activates MAPK through the dual speci®city MEK. To determine whether ®bronectin and heparin aect VEGF receptor tyrosine phosphorylation, T47D cells were stimulated with VEGF and total cell lysates were immunoprecipitated with anti-Flt-1, anti-Flk-1 or antiFlt-4 antibodies and subjected to immunoblotting with an anti-phosphotyrosine antibody. As indicated in Figure 6 , the tyrosine phosphorylation was increased upon cell stimulation with VEGF on plastic. When cells were seeded on ®bronectin, a greater increase in tyrosine phosphorylation was observed in response to VEGF in the presence of heparin. Although Flk-1 and Flt-4 showed a slight increase in tyrosine phosphorylation in the presence of heparin and ®bronectin as compared to cells seeded on plastic, a signi®cant increase in tyrosine phosphorylation, upon VEGF treatment, was observed with the Flt-1 receptor ( Figure  6a ). This suggests that the Flt-1 receptor could be responsible for the signaling observed in the T47D cells, although it is not the only receptor expressed on these cells. 
VEGF-induced PI3K activity is affected by heparin and fibronectin
Tyrosine phosphorylation of receptors can activate PI3K, which in turn phosphorylates and consequently activates the serine/threonine kinase AKT (Carpenter and Cantley, 1996) . AKT is activated by its PI3K-dependent recruitment to the plasma membrane that is followed by its phosphorylation at Thr-308 and Ser-473 residues (Downward, 1998) . Therefore, measurement of Ser-473 phosphorylated AKT can be an indication of PI3K/AKT pathway activation (Altiok et al., 1999; Downward, 1998) . Stimulation of T47D cells by VEGF modestly increased PI3K activity over the basal level, as indicated by the phosphorylation of phospholipids (Figure 7a ) and by AKT phosphorylation (*p-Akt, Figure 7b ). This modest increase in PI3K activity was weaker than in cells stimulated with heregulin (Figure 7a,b) . A signi®cant increase in PI3-kinase activation was observed when heparin was present with VEGF in the T47D cells grown on plastic. A slightly higher intensity of VEGF-induced PI3-kinase activity was observed in T47D cells grown on ®bronectin (Figure 7a,b) . Similar to heparin, dextran sulfate enhanced Akt phosphorylation in the presence of VEGF, while chondroitin sulfate was without eect (Figure 7b ). The increase in VEGFdependent PI3K activity was completely blocked by pretreatment of cells with the inhibitor LY294002, while PD98059 had no eect. Neither heparin (for both methods), nor dextran sulfate (for the *p-Akt assay, data not shown), alone aected the low basal level of AKT phosphorylation of the quiescent T47D cells. Equal amounts of AKT proteins were observed in all samples ( Figure 7b , lower panel).
Discussion
Our recent study (Price et al., 2001) , as well as investigations by others (Blancher et al., 2000; de Jong et al., 1998b; Speirs and Atkin, 1999; Yoshiji et al., 1996) , have demonstrated that breast cancer cells express both VEGF and VEGF receptors. However, VEGF alone was not able to induce either a proliferative or migratory response in T47D cells (Price et al., 2001) . Only cells that were seeded onto ®bronectin-coated membranes migrated in signi®cantly higher numbers than cells seeded on matrigel. Given that VEGF and its receptors possess regions rich in basic amino acids that confer binding to the ECM (Cardin and Weintraub, 1989; Dougher et al., 1997; Templeton, 1992) , and that VEGF binds to VEGF receptors in breast cancer cells via its exon 7-encoded ECM-binding region (which is not present in VEGF 121 ) (Soker et al., 1996) , it was reasonable to postulate that VEGF-induced signaling in T47D cells depends on an ECM component. Thus, the eects of heparin and ®bronectin on these cells were considered. In endothelial cells, VEGF binds with high-anity to its receptors (Cohen et al., 1995; Gitay-Goren et al., 1992). In spite of its high-anity binding, heparin Dougher et al., 1997; Gitay-Goren et al., 1992) and HSPGs (Gengrinovitch et al., 1999) Figure 7 Eect of heparin and ®bronectin on VEGF-dependent PI3K activity. Cells were seeded on PL or FN as described in Materials and methods. After 15-min treatment with VEGF, VEGF in the presence of heparin (VEGF+H), chondroitin sulfate (CS), or dextran sulfate (DS), or after treatment with heregulin (HRG), or with heparin alone, total cell lysates were subjected to either in vitro PI3K assay (a) or to immunoblotting (b). Untreated cells (control) or cells pretreated with either PD98059 (50 mM, PD) or LY294002 (10 mM, LY) were subjected to treatment with VEGF in the presence of heparin (H). (a) Immunoprecipitates with anti-phosphotyrosine antibodies were tested for their ability to phosphorylate lipids in the presence of g[ ]thymidine incorporation and no increase in the number of migrating cells after treatment with VEGF on matrigel. Accordingly, T47D cells in response to VEGF on plastic showed very modest increases in overall tyrosine phosphorylation, c-fos induction, MAPK activity and PI3K activation as opposed to quiescent cells. The degree of activation was several times lower than that observed in heregulin-treated cells; (ii) heparin presence and/or attachment to ®bronectin-coated plates was sucient to establish the mitogenic response and increase migration of these breast cancer cells in response to VEGF similar to the response elicited by heregulin, a potent breast cancer cell mitogen; (iii) signaling pathways that lead to proliferation such as MAPK and c-fos or that stimulate cell migration, such as PI3K, were signi®cantly increased in response to VEGF when cells were exposed to heparin and/or seeded onto ®bronectin-coated dishes; (iv) as suggested by Soker et al. (1996) , heparin/HSPGs enhance binding of VEGF to its receptors, and ®nally, (v) VEGF 121 , which does not possess an ECM binding domain, had no eect on DNA synthesis in the presence or absence of heparin and/or ®bronectin, while EGF strongly induced DNA synthesis which was not aected by the presence of either ®bronectin or heparin. Thus, in order to stimulate signaling in T47D cells, the binding of VEGF to its receptors needs to be stabilized by the presence of ECM components such as heparin and ®bronectin.
Although the binding of both VEGF and its receptors to heparin has been suggested by several authors Dougher et al., 1997; Gitay-Goren et al., 1992) , their binding to ®bronectin and its stabilizing role in the VEGF ± VEGF receptor complex have not been reported to date. Cells primarily interact with ®bronectin through b 1 integrins (Clark and Brugge, 1995) , while cooperative signaling from transmembrane HSPGs results in assembly of focal adhesions and actin stress ®bers (Saoncella et al., 1999) . Fibronectin contains several binding domains including those for ®brin, collagen, heparin and cellsurface receptors (Paolella et al., 1988) , and it has been shown to augment cell migration (Clark et al., 1988) . Its two heparin-binding domains, one of low anity and the other of high anity, are located at its N-and C-termini, respectively (Paolella et al., 1988) . The binding of the heparin-binding domain of ®bronectin to cell surface HSPGs promotes activation of PKC (Woods et al., 1993) . This result could be duplicated in our system, as cells seeded on ®bronectin showed the increased tyrosine phosphorylation of a protein migrating at *120 kDa (Miralem and Avraham, unpublished observation) . Although the nature of that band was not further investigated, its molecular weight and the fact that it is more phosphorylated in cells grown on ®bronectin suggest that this band could be FAK. Activated PKC and FAK could lead to MAPK activation, which induces c-fos transcription such as that observed in our present work. The eect of ®bronectin also could be attributed to the speci®c peptide PHSRN contained in its molecule, that was recently reported to accelerate wound healing by increasing cell invasiveness (Livant et al., 2000) .
The suppressive eect of poly-L-lysine on DNA synthesis suggests the involvement of integrins, which may mediate signaling from matrices containing ®bronectin, matrigel or collagens type I and IV. However, a partial inhibition of VEGF-dependent migration (Figure 1b ) and DNA synthesis (Table 1) by blocking anti-b 1 -integrin antibodies indicates that this mechanism is not the sole process. Integrins might also play a role in inducing the inhibitory eect of collagen type IV. Collagen type IV was shown to inhibit proliferation of melanoma cells (Han et al., 1997) and breast cancer cells (Shahan et al., 1999a) by up to 67%. This inhibition was attributed to the Serine-N-Serine sequence of the a3(IV) collagen chain. Integrin a v b 3 and integrin-associated protein CD47 were also responsible for this eect (Shahan et al., 1999b) . Although collagen type IV peptides were added to the growth medium (Shahan et al., 1999b) , it is conceivable that in our experiments (where cells were seeded onto a collagen type IV coat) cells were also exposed to the a3(IV) chain, which exerted its antiproliferative eect.
Breast cancer cells express VEGF receptors. Speirs and Atkin (1999) reported the presence of Flt-1 and Flk-1/KDR in breast cancer epithelial cells, while de Jong et al. (1998a) found signi®cant expression of these molecules in 50% of breast tumor epithelial cells. Consistent with these ®ndings, we recently reported the expression of Flt-1 and Flk-1 in several cell lines including T47D breast cancer cells (Price et al., 2001) . The results presented here suggest the presence of the Flt-4 receptor in addition to the Flt-1 and Flk-1 receptors in T47D cells. However, the increased signal from the Flt-1 receptor in the presence of ®bronectin and heparin was the most prominent, followed by that from Flt-4 and Flk-1/KDR. The reason for the weak activation of the Flt-4 receptor could be attributed to its lack of responsiveness to VEGF 165 . A shorter form of VEGF protein, VEGF-C, which has about 30% identity with VEGF 165 (Joukov et al., 1996) , has the highest anity for the Flt-4 receptor. Heparin binding anity has been identi®ed for Flt-1 , and also for Flk-1/KDR (Dougher et al., 1997) . Both receptors are associated with heparan sulfates or heparin-like molecules on the cell surface . This may have implications for the binding of VEGF. Indeed, binding of VEGF to VEGF receptors was dierentially regulated by heparin. For example, binding of VEGF to Flt-1 was inhibited whereas binding to Flk-1/KDR was stimulated . Our results showed that the presence of heparin and ®bronectin increased the activity of all VEGF receptors. These results, reporting the most signi®cant increase in activity and presumably binding of VEGF to Flt-1 in the presence of heparin and ®bronectin, are dierent than those presented by Terman et al. (1994) . These dierences may represent the dierent experimental conditions and cell types used.
Signal transduction by tyrosine kinase receptors, such as VEGF, depends upon the binding of SH2-SH3 domain-containing proteins to tyrosine phosphorylation sites on the receptor (Shibuya et al., 1999) . Subsequent MAPK activation converges from several pathways, one emanating from the activation of PLC-g through PKC and, another, through the Ras/MEKdependent cascade (Guo et al., 1995) . Decreased MAPK activity, such as that observed in VEGFtreated T47D cells grown on plastic, is consistent with low mitogenic response and weak c-fos induction. Strong and sustained activity of MAPK is required for its translocation to the nucleus where the enzyme activates transcription factors (Traverse et al., 1992) . Likewise, as indicated in the present study, plating of T47D cells onto ®bronectin, or onto plastic in the presence of heparin, signi®cantly increased all the signaling components tested in response to VEGF, providing the additional requirements for cells to complete passage through the S phase. The phosphorylated VEGF receptor can also recruit the p85 subunit of PI3K (Cunningham et al., 1995; Guo et al., 1995) , thereby activating the PI3K/AKT pathway. Activated PI3K/AKT may regulate cell survival (Downward, 1998) , proliferation (Chung et al., 1994; Thakker et al., 1999) , and migration (Fujikawa et al., 1999) . We have observed migration of T47D cells in response to VEGF only when heparin and/or ®bronectin was present on the transwell membrane, suggesting that both the growth factor and the ECM components are important in potentiating the migration of tumor cells. In endothelial cells, the PI3K pathway was shown to be crucial in cell survival (Gerber et al., 1998) and to play an important role in the regulation of cell migration (Fujikawa et al., 1999; Radisavljevic et al., 2000) . Similarly, in our system, we found that PI3K is involved in the regulation of cell survival (Price et al., 2001) as well as in the process of cell migration, because LY294002, a PI3K speci®c inhibitor, strongly inhibited the VEGF-dependent migratory response while PD98059 and U0126 speci®c MEK inhibitors, had a moderate eect. Our results are consistent with those of Adam et al. (1998) , who reported that MCF-7 cells, another breast cancer cell line, migrated in response to heregulin through a PI3K-mediated process (Adam et al., 1998) .
Induction of c-fos by growth factors operates through initial tyrosine phosphorylation of activated receptors, leading to subsequent MAPK activation. This induction is sensitive to inhibition of either tyrosine phosphorylation or MEK. Activation of MAPK leads to phosphorylation of the transcription factor Elk, which drives transcription of c-fos through serum response elements in the c-fos promoter (Treisman, 1994). PI3K was also shown to contribute to the cell cycle by inducing the AKT-dependent phosphorylation of glycogen synthase kinase 3 (Cross et al., 1995) and by activating protein-serine/threonine p70 S6 kinase (Chung et al., 1994) . However, our results strongly suggest that the PI3K-dependent pathway does not play a signi®cant role in VEGF-induced c-fos transcription in T47D cells. First, the c-fos mRNA level was not markedly reduced by pretreatment with LY294002, whose speci®city to PI3K has been demonstrated (Vlahos et al., 1994) . Additionally, the VEGF-dependent increase in the level of c-fos mRNA was abolished after cell pretreatment with PD98059. Finally, corroborating our results, it was recently reported in the HUVEC system that the PI3K and MAPK pathways do converge (Thakker et al., 1999) . However, PI3K was shown to be upstream of MAPK and to only aect induction of c-fos through the regulation of MAPK activity. The signi®cant increase in c-fos transcription in response to VEGF could be attributed to the speci®c eect of heparin because dextran sulfate alone, an unrelated polyanion, caused a strong increase in c-fos induction. Chondroitin sulfate, a control for GAG chains, was without eect either on c-fos induction or MAPK or PI3K activation. The induction of c-fos transcription by dextran sulfate alone supports the notion that part of heparin's eect is through electrostatic stabilization of the binding complex. For example, the binding anity of FGFs to heparin, which is a highly sulfated GAG, is greater than that to heparan-sulfate, a GAG that is less sulfated (Templeton, 1992) . However, the high isoelectric point, by itself, is insucient to explain the binding, because PDGF, with an isoelectric point similar to b-FGF, does not localize to anionic heparan sulfate sites on the basement membrane of the eye, whereas a-FGF and b-FGF do bind to the same sites (Jeanny et al., 1987) .
Extracellular matrix-induced oligomerization appears to be an important mechanism in regulating the biological activities of growth factors (Chirgadze et al., 1999) . Since breast cancer cells express Flt-1 and Flk-1/KDR receptors (de Jong et al., 1998a; Price et al., 2001; Speirs and Atkin, 1999) and secrete VEGF (Blancher et al., 2000; Price et al., 2001; Yoshiji et al., 1996) , this phenomenon may emphasize an autocrine mechanism by which VEGF increases the tumorigenicity of breast cancer cells. In the early stages of breast cancer development, there is an initial accumulation of ECM components in both the interstitial stroma (Christensen, 1992) and in the basement membrane (Ormerod et al., 1985) . Accumulated ECM, such as ®bronectin and HSPGs, may increase the responsiveness of breast cancer cells to VEGF by maintaining the stability of the complex between the growth factor and its receptor resulting in receptor activation. This could increase tumorigenicity through the stimulation of cell proliferation, survival and invasiveness. However, this initial phase does not seem to last very long due to a general decrease in ECM components and in the level of sulfation of heparan sulfate, which has been associated with the metastatic phenotype of cancer cells. This ®nal stage of transformation can be ascribed to the upregulation of ECM-degrading matrix metalloproteinases (Sternlicht et al., 2000) .
In this report, we demonstrated that VEGF requires the presence of ECM components for the induction of mitogenic and migratory responses in T47D cells. As compared to T47D cells grown on plastic, cells seeded on ®bronectin or cells grown on plastic in the presence of heparin had signi®cantly higher [ 3 H]thymidine incorporation and c-fos induction as well as a higher number of cells migrating to the transwell membranes. Likewise, intracellular signaling that supports mitogenic and migratory responses, such as tyrosine phosphorylation of VEGF receptors, MAPK activity, and PI3K activity, was much greater in cells seeded on ®bronectin or seeded on plastic in the presence of heparin, as compared to cells grown on plastic. Heparin has been shown to enhance the binding of VEGF to its receptors in both breast cancer (Soker et al., 1996) and endothelial cells (Gitay-Goren et al., 1992) , and ®bronectin has been reported to enhance VEGF 165 -dependent DNA synthesis in endothelial cells (Soldi et al., 1999) . However, to our knowledge, this is the ®rst report associating ECM enhancement of VEGF binding to the induction of mitogenic and migratory responses in breast cancer cells.
Materials and methods
Materials
Antibodies used for immunological analysis were as follows: anti-phosphotyrosine antibody (4G10) was from Genentech (San Francisco, CA, USA). Phospho-Erk (E-4) antibody, anti-Erk-2 (C-154), anti-Flt-1 antibody, anti-Flt-4 antibody, anti-Flk-1 antibody and HRP-labeled secondary antibodies were from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Anti-Akt, and anti-phospho-Ser-473 Akt antibodies were from New England-Biolabs (Beverly, MA, USA). Anti-phosphotyrosine antibody (PY20) was from Transduction Laboratories (Lexington, KY, USA). Genistein, LY294002, heparin, chondroitin sulfate A, and C, dextran sulfate, and phosphatidylinositol were from Sigma Chemical Co. (St. Louis, MO, USA). PD98059 and U0126 were from Calbiochem-Novobiochem Co. (La Jolla, CA, USA). VEGF 165 and heregulin were generous gifts from Genentech and VEGF 121 was from R&D Systems (Minneapolis, MN, USA). EGF was from Upstate Biotechnology (Lake Placid, NY, USA). g[ Cell culture T47D cells were obtained from ATCC. These cells were cultured in RPMI-1640 medium (Gibco-BRL), supplemented with 3.5 mg/ml insulin, 10% fetal bovine serum (Gibco-BRL), and penicillin/streptomycin. To coat the plates: human plasma ®bronectin (30 mg/ml), collagen type IV (40 mg/ml) and Matrigel (Engelberth-Holm-Swarm tumor basement membrane, 40 mg/ml) (Becton-Dickinson, Bedford, MA, USA) were dissolved in sterile water, 0.05 M HCl, or in cold medium, respectively, spread on culture dishes (1.2 ml/10-cm petri dish, 70 ml/well in 24-well plates), and allowed to dry in a sterile environment. Collagen type I solution (2.9 mg/ml) was purchased as Vitrogen-100 (Cohesion, Palo Alto, CA, USA) and was added to the wells of the tissue culture plates (0.25 ml/well in 24-well plates), then incubated for at least 60 min at 378C to gel. Poly-L-lysine (40 mg/ml, Sigma) was dissolved in water spread on culture dishes (70 ml/ml in 24-well plates) and allowed to dry in a sterile environment. Quiescence was induced by replacing growth medium on cells at 60 ± 80% con¯uence with medium containing 0.4% FBS, then followed by 48 h incubation. To study the initiation of signaling, cells were stimulated with heregulin (20 nM), or FBS (10%), VEGF (100 ng/ml), VEGF121 (100 ng/ml), or EGF (10 ng/ml) alone or in the presence of heparin, chondroitin sulfate, or dextran sulfate (all at a concentration of 1 mg/ml).
Cell attachment
Cell attachment was performed as described (Miralem et al., 1996b) . Brie¯y, labeled or unlabeled cells were released from petri dishes by trypsinization, resuspended in Dulbecco's modi®ed Eagle's medium (DMEM) containing bovine serum albumin (BSA; 1 mg/ml) and then seeded in 12-well plates that were either uncoated or precoated with ®bronectin (30 mg/ml). After 60 min, the percentage of attached cells was measured by both the direct counting of attached and unattached cells using a Coulter counter or by scintillation counting of radiolabeled cells as described by Grinnell and Feld (1979) . The per cent attachment was calculated as 1006[attached/(attached+unattached)].
Radioiodination
The iodination of VEGF 165 was carried out using IODO-GEN (Pierce, Rockford, IL, USA) as described previously (Soker et al., 1996) . 125 I-VEGF was then puri®ed by heparin anity chromatography in the presence of gelatin (10 mg/ml). Aliquots of the iodinated VEGF were frozen on dry-ice and stored at 7708C until needed. The speci®c activity of Binding and cross-linking T47D cells were grown in 24-well plates or in 60 mm petri dishes. After reaching con¯uency, they were transferred to an ice-cold environment and washed twice with ice-cold PBS.
125
I-VEGF (10 ng/ml) was added to F12 medium containing 25 mM HEPES (pH, 7.5) and 0.2% gelatin, and cells were then incubated for 4 h at 48C. At the end of the incubation, cells were washed three times with ice-cold PBS supplemented with 0.1% BSA, lysed in buer containing 1% Triton X-100 and 0.1% BSA, and counted in a g counter for recovered radioactivity. For the cross-linking studies; following incubation for 4 h in 60 mm plates, cells were treated with PBS containing disuccinimidyl suberate (0.15 mM) and the reaction was stopped by the addition of 200 ml of quenching buer (10 mM Tris-HCl, pH 7.5, 200 mM glycine, and 2 mM EDTA). Cells were then washed with ice-cold PBS, scraped in PBS containing 1 mM PMSF and 1 mM EDTA and centri-fuged for 30 s prior to dissolving pellets in lysis buer (10 mM Tris-HCl, pH 7.0, 0.5% Nonidet P-40, 0.5% Triton X-100, 0.1 mM EDTA, and 1 mM PMSF). The suspension was centrifuged and aliquots from the supernatant were analysed by SDS ± PAGE followed by autoradiography.
Mitogenic response
Mitogenic response of T47D cells was performed as previously described (Miralem et al., 1996b) . Brie¯y, cells were passaged at 10 5 cells/well (24-well plate) and grown either on plastic, ®bronectin, collagen type I or IV, Matrigel, and poly-L-lysine-coated plates and starved to arrest cell growth. A mitogenic response in the quiescent cells was induced with VEGF, VEGF 121 , EGF, heregulin, or fetal bovine serum, and measured by [ 3 H]thymidine (6.7 Ci/mM, 2 mCi/ml for 45 min) incorporation at dierent time points up to 24 h. After being labeled with [ 3 H]thymidine, cells were washed three times with 5% trichloroacetic acid at 08C, dissolved with 0.1 M NaOH, and radioactivity was measured by using scintillation counter.
RNA isolation and Northern blotting
Total RNA was isolated using an RNA kit from QIAGEN. The electrophoresis and blotting were done as described (Miralem et al., 1996a) . Brie¯y, equal amounts of RNA (*15 mg) were denatured, separated by electrophoresis on agarose-formaldehyde gels, and transferred to a Hybond-N nylon membrane (Amersham-Pharmacia Biotech). Membranes were hybridized with c-fos cDNA that was labeled with a-32 P-dCTP. Levels of mRNA were normalized to 18S rRNA after probing stripped blots with labeled cDNA to rat 18S rRNA. 32 P labeling of probes was carried out with a random primer DNA labeling kit from Boehringer-Mannheim (Indianapolis, IN, USA). The rat c-fos cDNA, cloned by T Curran (11), and the mouse 18S rRNA were obtained from DM Templeton (University of Toronto, Ontario, Canada).
MAPK activity
MAPK activity was determined by the ability of the immunoprecipitated enzyme to phosphorylate myelin basic protein (MBP) (Ahn et al., 1990) in an in vitro kinase assay. Immunoprecipitates were mixed with assay buer containing 20 mM HEPES (pH 7.4), 10 mM MgCl 2 , 2 mM MnCl 2 , 0.5 mM EGTA, 10 mM NaF, 0.5 mM Na 3 VO 4 , 1 mM dithiothreitol, 0.5 mg/ml MBP, 100 mM ATP, and 5 mCi of [g-32 P]ATP, and incubated at 308C for 30 min. The reaction was stopped by the addition of sample buer for electrophoresis according to Laemmli (1970) , and the mixture was separated on 15% SDS ± PAGE for silver staining and autoradiography.
PI3K activity
Cells were lysed in buer A containing 137 mM NaCl, 20 mM Tris-HCl, pH 7.4, 1 mM CaCl 2 , 1 mM MgCl 2 , 1% NP-40, 1 mM PMSF and 0.1 mM Na 3 VO 4 , and then cytosolic extracts were immunoprecipitated with anti-phosphotyrosine antibody (PY20). Precipitates were subjected to an in vitro kinase assay using g[ 32 P]ATP and phosphatidylinositol as substrates, according to Derman et al. (1996) . Brie¯y, beads were washed and incubated for 10 min at room temperature in kinase buer containing 0.5 mM ATP, 20 mM MgCl 2 , 50 mM HEPES, pH 7.0, 0.25 mg/ml phosphatidylinositol and 
Immunoblotting
Cells were lysed in the lysis buer A, and lysates or immunoprecipitats were subjected to SDS ± PAGE according to Laemmli (1970) . Separated proteins were transferred to PVDF membranes in 25 mM Tris and 192 mM Glycine (pH 8.3) containing 15% methanol, and then blocked with 5% BSA and 5% Carnation milk in 30 mM Tris-HCl (pH 7.4) containing 137 mM NaCl, 2.6 mM KCl and 0.05% Tween 20. Membranes were then probed with either anti-Erk-2 antibody, polyclonal rabbit anti-phospho-Erk antibody, monoclonal mouse anti-phosphotyrosine antibody 4G10, monoclonal mouse anti-actin antibody, polyclonal rabbit anti-Akt, polyclonal rabbit anti-Flt-4 antibody, monoclonal mouse anti-Flk-1 antibody, polyclonal goat anti-Flt-1 antibody or polyclonal rabbit anti-phospho-Ser-473 Akt antibodies, and immunoreactive bands were detected with the NEN-Biolab (Boston, MA, USA) enhanced chemiluminescence system, followed by autoradiography.
Migration assay
Transwell membranes (Corning Costar Corporation, Cambridge, MA, USA) were coated with matrigel (MTR; 2.5 mg/ ml) or MTR plus ®bronectin (30 mg/ml), and dry coatings were exposed to DMEM for 1 ± 2 h prior to cell passage. Cells were trypsinized, centrifuged and resuspended at approximately 10 7 /ml in DMEM containing 0.2% BSA, and then seeded onto precoated transwells in the same medium alone (control) or in medium supplemented with heparin (1 mg/ml), HRG (20 nM), VEGF (100 ng/ml), VEGF+hepar-in, VEGF 121 (100 ng/ml) or VEGF 121 +heparin. Some cells were pretreated for 30 min either with genistein (10 mM), PD98059 (50 mM), U0126 (10 mM), or LY294002 (10 mM) prior to cell detachment, or with blocking anti-b 1 integrin (10 mg/ml) or blocking anti-a 6 integrin (10 mg/ml) antibodies prior to treatment with VEGF in the presence of heparin. The bottom wells of the transwell contained 600 ml of the same medium as the upper wells but without the cells. After 24 h, the membranes were swabbed with Q-tips and exposed to methanol, followed by treatment with crystal violet prior to counting cell number under a phase-contrast microscope.
Abbreviations VEGF, vascular endothelial growth factor; HRG, heregulin; MTR, matrigel; ECM, extracellular matrix; GAG, glycosaminoglycan; PI3K, phosphatidylinositol 3-kinase; ERK, extracellular regulated kinase; MAPK, mitogenactivated protein kinase; PDGF, platelet-derived growth factor; FBS, fetal bovine serum; SDS ± PAGE, sodium dodecyl sulfate-polyacrylamide gel electrophoresis; HSPG, heparin sulfate proteoglycan; FN, ®bronectin, MEK, mitogen-activated kinase-kinase; AKT, Akt kinase; a-, b-FGF, acidic-, basic-®broblast growth factor.
Note added in proof
Unless otherwise stated, all notation of VEGF refers to the VEGF 165 isoform.
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